Mylan N.V. has launched in the United States its lidocaine patch 5%, which is the generic version of Endo Pharmaceutical’s Lidoderm. Mylan received final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated for relief of pain associated with post-herpetic neuralgia.

Lidocaine patch 5% had US sales of approximately $1.1 billion for the 12 months ending June 30, 2015, according to IMS Health, and as reported by Mylan.

Source: Mylan